Pembrolizumab ‐induced interstitial lung disease following thoracic surgery in a patient with non‐small cell lung cancer

The safety of treatment with immune ‐checkpoint inhibitors prior to thoracic surgery in patients with non‐small cell lung cancer (NSCLC) remains unclear. Here, we describe the case of a 62‐year‐old woman with NSCLC with programmed death ligand 1 expression on 85% of tumor cells. The patient was initially considered to have unr esectable stage IIIB disease and received pembrolizumab monotherapy. After 12 cycles of pembrolizumab, the primary tumor was reduced, but a small lung nodule in another lobe was unchanged. Based on the course of image findings, the nodule was considered to be an old inflammatory change. The clinic al stage was changed to stage IB and partial resection was performed. Three days after thoracic surgery, the patient began to complain of coughing and shortness of breath. A CT of the chest revealed ground‐glass opacity in the bilateral lung fields, suggesting interstitial lung disease (ILD) assoc iated with pembrolizumab. Corticosteroid therapy was started and a chest X‐ray showed a reduction in the opacity with improved oxygenation. This is the first case of immune‐checkpoint inhibitor‐related ILD triggered by thoracic surgery following long‐term immune‐checkpoint therapy.

Source: Thoracic Cancer - September 10, 2019 Category: Cancer & Oncology Authors: Tetsuo Fujita, Nami Hayama, Tsuguko Kuroki, Yuka Shiraishi, Hiroyuki Amano, Makoto Nakamura, Satoshi Hirano, Nao Aramaki, Shuji Ichinose, Shinichiro Shimizu, Hiroshi Tabeta, Sukeyuki Nakamura Tags: CASE REPORT Source Type: research